Researchers at Brown University have created a brain-computer interface (BCI) with 200 electrodes providing 48 megabits per second (Mbit/s) of neural signals.

Buck Institute researchers have discovered and are developing a novel, non-invasive biomarker test that can be used to measure and track performance of senolytics: a class of drugs that selectively eliminate senescent cells. The discovery is expected to play a major role in efforts to develop treatments that would battle a myriad of chronic age-related conditions that range from arthritis to lung disease to Alzheimer’s disease and glaucoma. This biomarker is a unique signaling lipid metabolite, normally exclusively intracellular, but is released when senescent cells are forced to die. This metabolite is detectible in blood and urine, making non-invasive testing possible. With a growing list of senolytic drugs in development, detecting this metabolite via a companion test could verify performance of senolytic candidates.
“The list of age-related diseases definitively linked to cellular senescence keeps growing, as does the number of biotech companies racing to develop drugs to eliminate senescent cells,” said Buck professor Judith Campisi, Ph.D., senior scientist on the study. “While the field has never been more promising, the lack of a simple biomarker to measure and track efficacy of these treatments has been a hindrance to progress. We are excited to bring this new biomarker to the field and look forward to it being used in the clinic.”
The results of this study confirm a direct link, on a molecular level, between the gut microbiome and brain function.
Summary: Consuming high levels of sugar-sweetened beverages early in life may lead to memory problems during adulthood. Researchers found, compared to rats who consumed only water, those who drank sugar-sweetened beverages had difficulties in memory recall associated with the hippocampus. The study also found a link between specific changes in gut bacteria in rats who drank sugary drinks and impaired brain function.
Source: USC
New research shows how drinking sugary beverages early in life may lead to impaired memory in adulthood.
The study, published today in Translational Psychiatry, also is the first to show how a specific change to the gut microbiome — the bacteria and other microorganisms growing in the stomach and intestines — can alter the function of a particular region of the brain.
Bipolar disorder affects millions of Americans, causing dramatic swings in mood and, in some people, additional effects such as memory problems.
While bipolar disorder is linked to many genes, each one making small contributions to the disease, scientists don’t know just how those genes ultimately give rise to the disorder’s effects.
However, in new research, scientists at the University of Wisconsin-Madison have found for the first time that disruptions to a particular protein called Akt can lead to the brain changes characteristic of bipolar disorder. The results offer a foundation for research into treating the often-overlooked cognitive impairments of bipolar disorder, such as memory loss, and add to a growing understanding of how the biochemistry of the brain affects health and disease.
Gene editing has shown great promise as a non-heritable way to treat a wide range of conditions, including many genetic diseases and more recently, even COVID-19. But could a version of the CRISPR gene-editing tool also help deliver long-lasting pain relief without the risk of addiction associated with prescription opioid drugs?
In work recently published in the journal Science Translational Medicine, researchers demonstrated in mice that a modified version of the CRISPR system can be used to “turn off” a gene in critical neurons to block the transmission of pain signals [1]. While much more study is needed and the approach is still far from being tested in people, the findings suggest that this new CRISPR-based strategy could form the basis for a whole new way to manage chronic pain.
This novel approach to treating chronic pain occurred to Ana Moreno, the study’s first author, when she was a Ph.D. student in the NIH-supported lab of Prashant Mali, University of California, San Diego. Mali had been studying a wide range of novel gene-and cell-based therapeutics. While reading up on both, Moreno landed on a paper about a mutation in a gene that encodes a pain-enhancing protein in spinal neurons called NaV1.7.
Dr. Shawna Pandya MD, is a scientist-astronaut candidate with Project PoSSUM, physician, aquanaut, speaker, martial artist, advanced diver, skydiver, and pilot-in-training.
Dr. Pandya is also the VP of Immersive Medicine with the virtual reality healthcare company, Luxsonic Technologies, Director of the International Institute of Astronautical Sciences (IIAS)/PoSSUM Space Medicine Group, Chief Instructor of the IIAS/PoSSUM Operational Space Medicine course, Director of Medical Research at Orbital Assembly Construction (a company building the world’s first rotating space station providing the first artificial gravity habitat), clinical lecturer at the University of Alberta, podcast host with the World Extreme Medicine’s WEMCast series, Primary Investigator (PI) for the Shad Canada-Blue Origin student micro-gravity competition, member of the ASCEND 2021 Guiding Coalition, Life Sciences Team Lead for the Association of Spaceflight Professionals, sesional lecturer for the “Technology and the Future of Medicine,” course at the University of Alberta, and Fellow of the Explorers’ Club.
Dr. Pandya also serves as medical advisor to several space, medical and technology companies, including Mission: Space Food, Gennesys and Aquanauta, as well as the Jasper Dark Sky Festival Advisory Committee.
Dr. Pandya holds a Bsc degree in neuroscience from University of Alberta, a MSc in Space Studies from International Space University, an MD from University of Alberta, and a certification in entrepreneurship from the Graduate Studies Program at Singularity University.
Dr. Pandya is currently completing a fellowship in Wilderness Medicine (Academy of Wilderness Medicine), was granted an Honorary Fellowship in Extreme and Wilderness Medicine by the World Extreme Medicine organization in 2021, and was one of 50 physicians selected to attend the 2021 European Space Agency Space Medicine Physician Training Course. Dr. Pandya was named one of the Women’s Executive Network’s Top 100 Most Powerful Women in Canada in 2021, and a Canadian Space Agency Space Ambassador in 2021.
Dr. Pandya was part of the first crew to test a commercial spacesuit in zero-gravity in 2015. Dr. Pandya earned her aquanaut designation during the 2019 NEPTUNE (Nautical Experiments in Physiology, Technology and Underwater Exploration) mission. She previously served as Commander during a 2020 tour at the Mars Desert Research Station. Her expeditions were captured in the Land Rover short, released with the Apollo 11: First Steps film. She previously interned at ESA’s European Astronaut Center and NASA’s Johnson Space Center.
New data from Children’s National Hospital shows parental experience with a number of social determinants of health can ultimately impact brain development in utero, something researchers said should suggest future community health intervention among pregnant people. The data, published in JAMA Network Open, specifically found poorer brain development in fetuses among pregnant people with low socioeconomic status (SES), low educational attainment, and limited employment opportunity.
New data from Children’s National Hospital has found that social determinants of health like income, education, and occupation can impact fetal brain development, following that child into life.
As brain activity-dependent human genes are of great importance in human neuropsychiatric disorders we also examined the expression of these genes to postmortem RNAseq databases from patients suffering from various neurological and psychiatric disorders (Table 1). Datasets were chosen based on similarities in tissue processing and RNAseq methodology to our own protocol. We performed a PCA (Principal Component Analysis) of our fresh brain compared to postmortem brain from healthy, Parkinson’s, Schizophrenia, Huntington’s, and Autism brains for the top 500 brain activity-dependent genes that showed the greatest reduction in the healthy postmortem samples. The PCA revealed a significant separation between the 4 fresh samples and the postmortem samples, independent of whether or not the fresh tissue was from epileptic (high activity, H) or non-epileptic (low activity, L) brain regions (Fig. 2 J). This further demonstrates a selective reduction of activity-dependent genes in postmortem brain independent of whether the underlying tissue is electrically active or not.
The sudden removal of brain tissue from a living person in many ways mimics a catastrophic event that occurs with a hypoxic brain injury or a traumatic death with exsanguination. The human brain has high energy needs, estimated to be 10 times that of other tissues21. As a means to understand how the postmortem interval selectively affects some genes and not others in human neocortex, we performed RNAseq and histological analyses in cortical brain tissue as a function of time from 0–24 h at 24 °C in order to simulate a postmortem interval. Neuropathological examination of the tissue used for this study showed a normal-appearing cortical pattern with no histopathologic abnormalities. RNAseq analysis showed a loss of brain activity-dependent genes that were 3-times more prone to be degraded than expected by chance compared to more stable housekeeping genes (Table 2). The threshold to detect activity-dependent genes was related to the probability of being affected by the PMI. The higher the relative expression of the brain activity gene, the more it was enriched in the population of genes affected by the PMI. These findings confirm that genes involved in brain activity are more prone to degradation during the PMI.
One possible explanation for the selective loss of activity-dependent genes could relate to the stability of various cell populations during the simulated PMI. As a means to implicate specific cell populations that could be responsible for the reduction of genes during the simulated PMI we used a clustering algorithm as we have previously described9. We found that 1427 genes (71% known brain activity-dependent genes) could be clustered across the seven time points of the simulated PMI. For these clusters, we used AllegroMcode to identify two main clusters. One cluster of 317 rapidly declining genes was predicted to be neuronal and strongly overlapped with the activity-dependent genes. A second cluster of 474 genes was predicted to be glial, including astrocytes and microglia (Fig. 3A). Remarkably, as the neuronal cell cluster rapidly fell, there was a reciprocal and dramatic increase in the expression of the glial cell cluster (Fig. 3B).
Many of us have been wracking our brains why Nvidia would spend a fortune – a whopping $40 billion – to acquire Arm Holdings, a chip architecture licensing company that generates on the order of $2 billion in sales – since the deal was rumored back in July 2020. As we sat and listened to the Arm Vision Day rollout of the Arm V9 architecture, which will define processors ranging from tiny embedded controllers in IoT device all the way up to massive CPUs in the datacenter, we may have figured it out.
There are all kinds of positives, as we pointed out in our original analysis ahead of the deal, in our analysis the day the deal was announced in September 2020, and in a one-on-one conversation with Nvidia co-founder and chief executive officer Jensen Huang in October 2020.
We have said for a long time that we believe that Nvidia needs to control its own CPU future, and even joked with Huang that it didn’t need to have to buy all of Arm Holdings to make the best Arm server CPU, to which he responded that this was truly a once-in-a-lifetime opportunity to create value and push all of Nvidia’s technologies – its own GPUs for compute and graphics and Mellanox network interface chips, DPU processors, and switch ASICs – through an Arm licensing channel to make them all as malleable and yet standardized as the Arm licensing model not only allows, but encourages.
Summary: All-trans retinoic acid, a vitamin A derivative, induces synaptic plasticity in human cortical neurons.
Source: eLife.
The brain has an enormous capacity to adapt to its environment. This ability to continuously learn and form new memories thanks to its malleability, is known as brain plasticity.